 | Up a level |
Journal Article
Robak, Tadeusz, Hellman, Andrzej, Loscertales, Javier, Lech-Maranda, Ewa 
ORCID: 0000-0001-9592-0851, Pagel, John M., Mato, Anthony R., Byrd, John C., Awan, Farrukh ORCID: 0000-0003-1813-9812, Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Stromatt, Scott and Kloczko, Janusz
(2014).
Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR (TM) Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results.
Blood, 124 (21).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
Robak, Tadeusz, Hellmann, Andrzej, Kloczko, Janusz, Loscertales, Javier, Lech-Maranda, Ewa ORCID: 0000-0001-9592-0851, Pagel, John M., Mato, Anthony, Byrd, John C., Awan, Farrukh T., Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Eisenfeld, Amy J., Stromatt, Scott C. and Jaeger, Ulrich
(2017).
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Br. J. Haematol., 176 (4).
S. 618 - 629.
HOBOKEN:
WILEY.
ISSN 1365-2141